The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
 
Matthew Ingham
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech; Mirati Therapeutics
 
Michelle R. Mahoney
No Relationships to Disclose
 
Fabrizio Remotti
No Relationships to Disclose
 
Ardaman Shergill
No Relationships to Disclose
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - AADi (Inst); Lilly (Inst)
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Ignyta; Lilly; Loxo; NanoCarrier
Research Funding - AADi (Inst); Arog (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); NanoCarrier (Inst); Plexxikon (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Ignyta; NanoCarrier
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Anthony D. Elias
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Align Oncology; Allergan; Amgen; Boston Scientific; Bristol-Myers Squibb; CVS Health; Exact Sciences; Gilead Sciences; Illumina; Johnson & Johnson; Medtronic; Merck; Pfizer; Thermo Fisher Scientific; United Health Group
Consulting or Advisory Role - Ayala Pharmaceuticals
Research Funding - Astellas Pharma (Inst); Deciphera (Inst); Eisai (Inst); Genentech (Inst); Medivation (Inst); xencor (Inst)
(OPTIONAL) Uncompensated Relationships - HSIX
 
David A. Liebner
Consulting or Advisory Role - Blueprint Medicines; Epizyme; Foundation Medicine
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
Travel, Accommodations, Expenses - Blueprint Medicines; Epizyme; Foundation Medicine
 
Mark Agulnik
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Lilly; Regeneron
Speakers' Bureau - Bayer; Bristol-Myers Squibb
 
Katherine Anne Thornton
Consulting or Advisory Role - Adaptimmune; Agios; Lilly; Macrogenics; More Health
Expert Testimony - Kilcoyne & Nesbitt
 
Varun Monga
Consulting or Advisory Role - Forma Therapeutics
Research Funding - ImmunoCellular Therapeutics (Inst); Newlink Genetics (Inst); Orbus Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera (Inst); GlaxoSmithKline (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Johnson & Johnson; Lilly/ImClone; Novartis; Pfizer; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Deciphera; Eisai; EMD Serono; GlaxoSmithKline; Lilly; NanoCarrier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329